Weight was decreased significantly by amphetamines (in children and adolescents, SMD −0·71, 95% CI −1·15 to −0·27; in adults, −0·60, −1·03 to −0·18), methylphenidate (in children and adolescents, −0·77, −1·09 to −0·45; in adults, −0·74, −1·20 to −0·28), atomoxetine (in children and adolescents, −0·84, −1·16 to −0·52), and modafinil (in children and adolescents, −0·93, −1·59 to −0·26), compared with placebo (appendix pp 476, 477). Systolic blood pressure was increased with use of amphetamines (SMD 0·09, 95% CI 0·01–0·18) and atomoxetine (0·12, 0·02–0·22) in children and adolescents, and with use of methylphenidate (0·17, 0·05–0·30) in adults, compared with placebo (appendix p 477). Use of amphetamines (0·21, 0·12–0·31), atomoxetine (0·28, 0·18–0·37), and methylphenidate (0·24, 0·14–0·33) in children and adults, and atomoxetine (0·19, 0·08–0·30) and methylphenidate (0·20, 0·08–0·32) in adults, significantly increased diastolic blood pressure compared with placebo (appendix p 478).
